Canada markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4800-0.0700 (-4.52%)
At close: 04:00PM EDT
1.4300 -0.05 (-3.38%)
After hours: 04:10PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • c
    charlie
    This is exploding. What is happping to explain the strength?
  • M
    Mike
    Wow! What happened!
  • M
    Mike
    Is 30M just about their quarterly lose?
  • J
    Jack
    Where do we think this stock is going price
  • A
    Andreas
    will this survive?
  • M
    Mike
    CFO bought 60k shares
  • �
    💊C
    Why is this down?
  • S
    Stephen
    Looks to be gapping up this morning. News?
  • b
    bluehorseshoe999
    Most likely scenario is as follows:

    1. Complete P3 data so far get reported in Feb/March time frame.
    2a. Results are fantastic and thus, company goes to prepare for NDA in the fall
    2b. Additional fund are raised with PPS popping around 20 in preparation for NDA and continuing trials
    3. Continue trials to add to current data to NDA submission in the fall
    4. Drug gets PFUDA date some time in the middle of 2023 for approval...
    5. Drug gets approved.

    Fly in the ointment for shorts is that when new capital is raised PPS would have jumped significantly from current levels so covering with new issued shares would not be profitable. Big loss and a Big gamble in shorting here with all the good data so far on the drug!

    GLTA in stock casino!
  • C
    Charles
    While Galactosemia is to be approved in 5 months with Orphan designation and will generate sales to a small group of patienst of 300 to 500 million, likely to the lower end, the hidden value is the massive market of Diabetic Cardiomyopithy, that is a true blockbuster. It is in phase 2/3 trlals now, and is likley to be very successful. If success, then this company is a takeover candidate by big pharma.
  • J
    Jack
    Guess short sellers can do anything in this market, till the company release the next update, likely in March. Any long still here?
  • S
    SheTriedIt
    Looks like this is good to get into now to the tune of 2000-3000 shares. It has sustained $19-25 fairly consistently over the years.
  • R
    Ray Martyn
    Is APLT a buy at $30?
  • s
    stocktracker000
    BTW, strong support today at 6.10 or so...
  • b
    bluehorseshoe999
    Quite interesting!!!!

    Here is an excerpt from company PR:

    The ongoing ACTION-Galactosemia Kids Phase 3 study is evaluating the impact of AT-007 treatment vs. placebo on clinical outcomes over time, including cognition, speech, behavior and motor skills. Clinical outcomes are assessed every 6 months by a firewalled committee. The first assessment will be completed in the first quarter of 2022, and then every 6 months thereafter until the study reaches statistical significance.

    First assessment will be 1Q2022. Probably some time in March. If past data are any indication then it should be good results. Just have to wait and see and then every 6 months....

    Only have to wait about 2 months for first inkling on P3 data...

    GLTA in stock casino!
  • S
    Stephen
    Time to buy back in for a ride back up to $24, mark it.
  • R
    R
    Are we looking at bankruptcy?
  • T
    Tom
    There are about 2800 patients that need this.not a large market
  • L
    LU
    they pulled the IPO 1st time because market was down 1.5% now they pulled it the 2nd time because the market is down 3%, I am double checking when they are going with the 3rd attempt - the market will down roughly 4.5% on that day
  • m
    mark
    I think mgmt should decide they’re better off as part of another larger entity . Perhaps so